A Phase 4 interventional study of Radiofrequency ablation, antiarrhythmic drugs and Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs in Paroxysmal Atrial Fibrillation, sponsored by Biosense Webster, Inc.. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Biosense Webster, Inc. (part of Johnson & Johnson) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Atrial Fibrillation by Johnson & Johnson — 7 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Johnson & Johnson.
Among the 71 studies in Atrial Fibrillation by Johnson & Johnson, this one is the 35th largest by enrollment of the 58 interventional ones that give a count, is the only one that started in 2003, is one of 10 in phase 4, and was the 5th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.
Browse Atrial Fibrillation studies →7 of the 71 studies in Atrial Fibrillation by Johnson & Johnson are open now, in 5 countries. Recruiting first, the newest first:
Biosense Webster, Inc. · Sites in China
Ages 18–80
Johnson & Johnson Medical (Shanghai) Ltd. · Sites in China
Ages 18–80
Biosense Webster, Inc. · Sites in United States
Ages 18–80
Biosense Webster, Inc. · Sites in United States
Ages 18–80
Biosense Webster, Inc. · Sites in United States
Ages 22+
By country, each count listing its studies:
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 12 · Phase 4 10
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is below the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.
Median enrollment 149 across the 58 interventional studies, 426 across the 13 observational. Of the 57 that completed or were terminated, 39 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Biosense Webster, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Biosense Webster, Inc. is the lead sponsor of 64 studies on the registry; 8 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 24 (92%) have results posted.
6 of the studies in Atrial Fibrillation by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07429214Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF | 2026-12-30 |
| NCT07428564Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF | 2026-12-30 |
| NCT03963349Biosense Webster, Inc.THERMOCOOL SMARTTOUCH®SF Catheters With Ablation Index Study | 2026-12-31 |
| NCT07116525Biosense Webster, Inc.A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter | 2027-02-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 71 studies in Atrial Fibrillation by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Radiofrequency ablation, antiarrhythmic drugs · Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs
Radiofrequency catheter used.
Device: Radiofrequency ablation, antiarrhythmic drugs · Device: ThermoCool Radiofrequency Catheter
Patients receive either treatment.
Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.
Recurrence of Atrial Fibrillation
To compare the incidence of recurrence of Atrial Fibrillation in the two groups over a follow-up period of one year.
Time frame: One year
Efficacy of ablation and drug treatment
Evaluation of: * the functional state of the 2 groups of patients in terms of quality of life * the efficacy of the subgroup receiving amiodarone as compared to curative ablation * the incidence of secondary effects of both approaches * the rate of withdrawal from oral anticoagulation at 1 year after randomization * the effect of ablation for maintenance of sinus rhythm with previously ineffective drugs in case of failure of ablation strategy (after cross-over to medical treatment) * the assessment of Atrial fibrillation burden in both groups (using patient diaries and Holter Monitors)
Time frame: One year
Ran from Aug 2003 to primary completion in Jun 2006, 34 months.
Of 141 phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 81. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.